S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26

Nuvo Pharmaceuticals (MRVFF) Stock Forecast, Price & News

0.00 (0.00%)
(As of 05/25/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume
3,492 shs
Market Capitalization
$7.09 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MRVFF News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Nuvo Pharmaceuticals logo

About Nuvo Pharmaceuticals

Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$54.98 million
Cash Flow
$0.59 per share
Book Value
$1.33 per share


Net Income
$-25.69 million
Pretax Margin




Free Float
Market Cap
$7.09 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

0.13 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Nuvo Pharmaceuticals (OTCMKTS:MRVFF) Frequently Asked Questions

How were Nuvo Pharmaceuticals' earnings last quarter?

Nuvo Pharmaceuticals Inc. (OTCMKTS:MRVFF) released its quarterly earnings results on Monday, March, 28th. The company reported ($0.18) earnings per share (EPS) for the quarter. The company had revenue of $14.05 million for the quarter. Nuvo Pharmaceuticals had a negative trailing twelve-month return on equity of 29.09% and a negative net margin of 16.97%.
View Nuvo Pharmaceuticals' earnings history

Who are Nuvo Pharmaceuticals' key executives?
Nuvo Pharmaceuticals' management team includes the following people:
  • Mr. Jesse F. Ledger, Pres & CEO
  • Ms. Mary-Jane E. Burkett C.A., CPA, HBA, VP & CFO
  • Dr. Bernard Joseph Chiasson Ph.D., VP of Operations & Chief Scientific Officer
  • Ms. Katina K. Loucaides M.Sc., LL.B, VP, Corp. Sec. & Gen. Counsel
  • Mr. Luigi Berardelli, VP of Sales & Marketing
What is Nuvo Pharmaceuticals' stock symbol?

Nuvo Pharmaceuticals trades on the OTCMKTS under the ticker symbol "MRVFF."

How do I buy shares of Nuvo Pharmaceuticals?

Shares of MRVFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvo Pharmaceuticals' stock price today?

One share of MRVFF stock can currently be purchased for approximately $0.62.

How much money does Nuvo Pharmaceuticals make?

Nuvo Pharmaceuticals has a market capitalization of $7.09 million and generates $54.98 million in revenue each year. The company earns $-25.69 million in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Nuvo Pharmaceuticals have?

Nuvo Pharmaceuticals employs 100 workers across the globe.

What is Nuvo Pharmaceuticals' official website?

The official website for Nuvo Pharmaceuticals is www.nuvopharmaceuticals.com.

How can I contact Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals' mailing address is 6733 MISSISSAUGA ROAD SUITE 800, MISSISSAUGA A6, L5N 6J5. The company can be reached via phone at (905) 673-6980, via email at [email protected], or via fax at 905-673-1842.

This page was last updated on 5/26/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.